Tharimmune Board Changes and Officer Compensation
Ticker: CNTN · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1861657
| Field | Detail |
|---|---|
| Company | Tharimmune, INC. (CNTN) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, officer-compensation
TL;DR
Tharimmune director resigns, officer comp details released.
AI Summary
Tharimmune, Inc. announced on November 20, 2024, a change in its board of directors. Dr. Jonathan M. Roth, who served as a director, has resigned. The company also reported on compensatory arrangements for its officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are relevant to understanding executive incentives and potential dilution.
Risk Assessment
Risk Level: low — The filing reports routine board changes and compensation details, which are standard disclosures and do not indicate immediate significant financial or operational risks.
Key Players & Entities
- Tharimmune, Inc. (company) — Registrant
- Dr. Jonathan M. Roth (person) — Resigned Director
FAQ
When did Dr. Jonathan M. Roth's resignation from the board become effective?
The filing does not specify the exact effective date of Dr. Roth's resignation, only that it was reported on November 20, 2024.
What is Tharimmune, Inc.'s principal executive office address?
Tharimmune, Inc.'s principal executive office is located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.
What is Tharimmune, Inc.'s IRS Employer Identification Number?
Tharimmune, Inc.'s IRS Employer Identification Number is 84-2642541.
What is the SIC code for Tharimmune, Inc.?
The Standard Industrial Classification (SIC) code for Tharimmune, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What other items are reported in this 8-K filing besides director departure and officer compensation?
The filing also indicates 'Other Events' as an item information.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-11-21 16:51:46
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value THAR The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-24-047175.txt ( ) — 206KB
- thar-20241120.xsd (EX-101.SCH) — 3KB
- thar-20241120_lab.xml (EX-101.LAB) — 33KB
- thar-20241120_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 21, 2024 Tharimmune, Inc. /s/ Randy Milby Randy Milby Chief Executive Officer -3-